REFRACTORY MYELODYSPLASTIC SYNDROME
Clinical trials for REFRACTORY MYELODYSPLASTIC SYNDROME explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY MYELODYSPLASTIC SYNDROME trials appear
Sign up with your email to follow new studies for REFRACTORY MYELODYSPLASTIC SYNDROME, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New Three-Drug cocktail targets tough leukemia
Disease control TerminatedThis early-stage trial tests whether adding regorafenib to the standard venetoclax plus azacitidine regimen is safe and effective for adults with acute myeloid leukemia (AML) that has returned or not responded to prior treatment. About 20 participants will receive the combination…
Matched conditions: REFRACTORY MYELODYSPLASTIC SYNDROME
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 17, 2026 04:17 UTC
-
Experimental drug TAK-243 targets Hard-to-Treat blood cancers
Disease control TerminatedThis early-stage trial tests the safety and best dose of TAK-243 in about 42 adults with acute myeloid leukemia or myelodysplastic syndromes that have returned or are not responding to standard therapy. TAK-243 works by blocking enzymes that cancer cells need to grow. The study i…
Matched conditions: REFRACTORY MYELODYSPLASTIC SYNDROME
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 04:14 UTC
-
New hope for kids with relapsed leukemia: drug combo targets hidden cancer cells
Disease control OngoingThis early-phase trial tests a new drug called uproleselan combined with standard chemotherapy (fludarabine and cytarabine) in children and teens with acute myeloid leukemia, myelodysplastic syndrome, or mixed phenotype acute leukemia that has returned or not responded to treatme…
Matched conditions: REFRACTORY MYELODYSPLASTIC SYNDROME
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
New hope for hard-to-treat MDS: triple-drug combo tested in small trial
Disease control OngoingThis study tests a new combination of three drugs (navitoclax, venetoclax, and decitabine) in about 6 adults with high-risk myelodysplastic syndrome (MDS) that came back or didn't respond to initial treatment. The goal is to find the safest dose and see if the combo can shrink or…
Matched conditions: REFRACTORY MYELODYSPLASTIC SYNDROME
Phase: PHASE1 • Sponsor: Thomas Jefferson University • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
Experimental combo aims to outsmart resistant blood cancers
Disease control OngoingThis early-phase study tests a combination of two drugs—ipilimumab (an immunotherapy that helps the immune system attack cancer) and decitabine (a chemotherapy drug)—in adults with myelodysplastic syndrome or acute myeloid leukemia that has returned or not responded to prior trea…
Matched conditions: REFRACTORY MYELODYSPLASTIC SYNDROME
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New drug combo offers hope for Tough-to-Treat blood cancers
Disease control OngoingThis study tests a combination of two drugs, venetoclax and azacitidine, in people with high-risk myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) that has returned or not responded to prior therapy. The goal is to find the best dose and see how well the c…
Matched conditions: REFRACTORY MYELODYSPLASTIC SYNDROME
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 12, 2026 13:43 UTC
-
Targeted drug shows promise for Hard-to-Treat blood cancers with IDH mutation
Disease control OngoingThis study tests a drug called olaparib in adults whose acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) has returned or not responded to treatment and who have a specific change in the IDH gene. The drug works by blocking enzymes that cancer cells need to grow. The…
Matched conditions: REFRACTORY MYELODYSPLASTIC SYNDROME
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 08, 2026 12:01 UTC
-
New drug hunts and kills stubborn bone marrow cancer cells
Disease control TerminatedThis early-stage trial tests a new drug called lintuzumab-Ac225 for people with a high-risk type of myelodysplastic syndrome (MDS) that did not get better with standard treatments. The drug works like a smart bomb: it attaches to cancer cells and delivers a small dose of radiatio…
Matched conditions: REFRACTORY MYELODYSPLASTIC SYNDROME
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 07, 2026 18:38 UTC